Endometriosis Diagnostic Test Advances with $850,000 NIH Funding
Event summary
- The Feinstein Institutes’ ROSE study is developing a non-invasive diagnostic test for endometriosis using menstrual blood.
- The study has enrolled over 3,700 participants and is in Phase II clinical trials, comparing test results to surgical findings.
- The ROSE team received $850,000 in prize funding from the NIH’s RADx Tech program, building on previous awards.
- The ultimate goal is FDA approval for the test, aiming to reduce the average 6+ years women currently wait for a diagnosis.
The big picture
The diagnostic delay for endometriosis represents a significant unmet medical need, impacting millions of women globally and contributing to substantial healthcare costs. The ROSE study’s progress highlights the growing trend towards non-invasive diagnostics and personalized medicine in women’s health, potentially disrupting the traditional surgical-dependent diagnostic pathway. Success here could create a template for similar diagnostic advancements in other chronic conditions with delayed diagnoses.
What we're watching
- Regulatory Pathway
- The success of the ROSE study hinges on navigating the FDA approval process, which could be lengthy and require significant additional data demonstrating accuracy and clinical utility.
- Clinical Adoption
- Widespread adoption of the test will depend on physician buy-in and integration into standard gynecological practice, which may face resistance or require significant education.
- Commercialization
- Northwell Innovations' ability to effectively commercialize the test, including establishing distribution channels and pricing strategies, will be critical to recouping the substantial research investment.
Related topics